program (BioDiscovery Inc., CA, USA), which was initially used for analysis of array-data. The Nexus quality score (i.e. NQ) is an estimate of statistical variance of the differences in the intensity data (LRR) of adjacent probes after removing 3% outlying values. These three MZ pairs were suitable internal controls, allowing testing of whether the filters at different settings were discerning the three large-scale aberrations, thus allowing us to test the sensitivity of the method (for more information see Figure S4 ). Supplemental These settings filtered out random noise in a more efficient way as compared to 0.10 to 0.45 settings in Figure S2 , but not to the same extent as 0.20 to 0.45 settings shown in Figure S4 . This figure has a similar set up as Figures S2 and S4. Results in (A) and (B) are plotted including loci within three known large-scale de novo aberrations (red-dots; pair TP12-1/TP12-2 containing a terminal CNN-LOH of 76.47 Mb on 10q, pair TP25-1/TP25-2 with a 32.46 Mb deletion on 5q, and pair TP30-1/TP30-2 with a 12.91 Mb deletion on 20q) and in panels (C) and (D) the same data are plotted without the probes for these known aberrations (for more information see Figure S4 ). Panels (A) and (C) are showing data after filtering of intra-pair differences using delta-BAF filter only and panels (B) and (D) show results using delta-BAF in combination with delta-LRR filters. Each dot represents data from one MZ twin pair. These settings filtered out random noise in the most optimal way, when compared to settings in
Figures S2 and S3. Each dot represents data from one MZ twin pair and panels (A) and (C) show intra-pair differences using the delta-BAF filter only, while panels (B) and (D) show data using delta-BAF in combination with delta-LRR filters. Results in (A) and (B) are plotted including loci within three known large-scale de novo aberrations (red-dots; pair TP12-1/TP12-2 containing a terminal CNN-LOH of 76.47 Mb on 10q, pair TP25-1/TP25-2 with a 32.46 Mb deletion on 5q, and pair TP30-1/TP30-2 with a 12.91 Mb deletion on 20q) and in panels (C) and (D) the same data are plotted without the probes in these known aberrations. These three MZ pairs are suitable internal controls, allowing testing of whether the filters at different settings were discerning the three large-scale aberrations, thus allowing us to test the sensitivity of the pipeline shown in Figure S1 . Figure S5 . Two Large-Scale Genetic Aberrations Found in a 77-Year-Old MZ Twin TP12-2 using the Illumina SNP Array Twin TP12-1 shows a normal copy number profile (A, D, and E). Using B-Allele Frequency (BAF) a 76.5 Mb large copy number neutral loss of heterozygosity (CNN-LOH) was identified on 10q in co-twin TP12-2 (B, F, and G). Quantification of cells containing the CNN-LOH using the MAD package suggests that 34.4% of cells were affected. As expected, comparative genomic hybridization array (aCGH) could not detect this copy number neutral aberration (C). However, the TP12-2 twin also showed a monosomy of chromosome Y in a proportion of cells (B, J, and K) and this CNV was confirmed using aCGH (C). Three Illumina platforms (600K, 1M-Duo and 1M Omni) were used in the primary detection and validation of the results from this twin pair (details not shown). Validation of small-scale putative CNVs by array-comparative genomic hybridization using custommade maximum-resolution tiling-path oligonucleotide array (Nimblegen 135K) using co-twins (A-T).
Statistical significance for the results from the Nimblegen array was calculated using the MannWhitney U-test, analyzing values for region of interest (shaded) and on both sides flanking control regions. By co-hybridization of monozygotic twins we could successfully validate 52 (38%) loci displaying putative small-scale CNVs. The custom-made 135K Nimblegen array consisted of 137545 probes, which were used to validate the 138 putative CNV loci detected by the Illumina SNP array ( Figure 2B and Figures S1 and S4D ). In total, the design consisted of 98894 experimental probes (covering the chromosomal windows shown in Table S4 ) and an additional 38651 backbone control probes evenly distributed across the whole genome. Probe sequence length varied according to
Nimblegen recommendations between 50 and 75 bps and the median overlap of probes (i.e. probe spacing) was 30 bps. The rate of validation success was not different in the young (n=8) and old (n=26) MZ pairs used in these experiments (t-test, t=0.7062, p-value=0.4819) , supporting the results from linear regression analyses in Figure 2B and Figure S4D . Figures 1G-1K ). Analysis of Illumina data using R-package MAD suggest 58.4% aberrant cells at the age of 88. The subject was re-sampled at the age of 90, when both peripheral blood and a skin biopsy was obtained. The latter was used for short-term culture of fibroblasts. From peripheral blood we sorted CD4+-, CD19+-cells and granulocytes using standard protocols. When comparing whole blood at 88 and 90 years of age, the proportion of cells with CNN-LOH had decreased substantially in only two years (A, B, and G), from 57.8 to 29.9% according to the MAD-estimates. As expected, the fibroblasts sampled as control shows a normal BAF profile without the aberration (F and G). Results from different types of sorted blood cells at the age of 90 showed unexpected results (C-G) and we found significant differences in BAF-deviation between the cell types tested at this age (G, ANOVA; p<0.001, Tukey's test for multiple comparisons). Thus, the 4q CNN-LOH was readily detected in CD4+ cells and granulocytes as well as in whole blood, whereas it was absent in CD19+ cells. All estimates of percentages of cells with CNN-LOH presented in this figure were calculated using the MAD package.
Analysis of samples taken at the age of 90 was performed in duplicate genotyping experiments on Illumina 1M-Duo and Omni-Express arrays with very similar results. and the corresponding numbers for the ADVANCE cohort genotyped on the 550K platform were 0.5043 (S.E. ± 0.0023). This analysis shows that the BAF-variation of the 550K genotyping was more close to the theoretically expected 0.5 value, as compared to the 1M Duo results (t-test, p < 0.001).
Thus, the genotyping quality of ADVANCE cohort is at least as reliable as the results from ULSAM subjects. Error bars indicate standard errors. The raw data summarized in this figure are shown in Table S6 . Fig. 9 a -description of studied cohorts of monozygotic twins and single-born subjects is provided in Supplemental Table 2 . Table S1 . Summary of findings for monozygotic twins and single-born subjects from ULSAM cohort, which display mega-base range somatic structural genetic variants. The arbitrary limit of large-scale rearrangements has been set at 1 million basepairs (Mb).
MZ -monozygotic; CNN-LOH -copy number neutral loss of heterozygozity, also called segmental uniparental disomy; Mb -million base pairs.
Supplemental Table 1 , page 1 c -Somatic genetic variation in the highlighted regions of interest (ROI) was determined by comparing B allele frequency (BAF) and/or Log R Ratio (LRR) measurements between MZ twin of the same pair for a set of SNP loci. For subjects from ULSAM cohort, the somatic de novo nature of the rearrangements was established by examination of samples taken at other time points and comparing BAF and/or LRR measurements between samples at different ages. Significance was calculated by comparing the BAF or LRR differences in twins and ULSAM single born subjects within the ROI and a control region using the Mann-Whitney U test. The control regions for twins TP12-2, TP25-2, TP30-1 and D8 as well as for ULSAM-340 and ULSAM-697 were the remainder of each corresponding chromosome outside the ROI. For smaller aberrations on 1q and 8q in ULSAM-102, 1 million base pairs on both sides of the ROI was selected as control regions. Mb aber. -number of subjects with mega-base range aberration normal -number of subjects with normal profiles Description of studied cohorts: Table S2 I-X. Summary of somatic mega-base range aberrations detected in the studied cohorts of monozygotic (MZ) twins and single-born subjects. The arbitrary limit of large-scale rearrangements has been set at 1 million basepairs (Mb). the population based Swedish Twin Regsitry, who were separated before the age of 11 and reared apart and a matched sample of twins reared together. SATSA twins participated in up to 6 waves of questionnaires and 9 waves of in-person testing (IPT) during which a blood sample was collected. For the present investigation, 67 monozygotic pairs over the age of 60 years were selected. For 18 of these pairs, whole blood samples were available from 2 occasions at least 10 years apart and all samples at the second sampling were taken over the age of 60 years. For one additional monozygotic pair, samples available from two time points 7 years apart were also studied.
b NIH -Autoimmune: The MZ twin pairs from NIH are a subset of NIH-sponsored study on twins and close siblings discordant for a diagnosis of systemic autoimmune disease. For the present investigation, peripheral blood DNA from 22 young (age 3-43) MZ twin pairs discordant for autoimmune diseases was selected from among a group of 150 pairs who completed the study. Probands meet accepted criteria for adult or juvenile: 1) rheumatoid arthritis; or 2) systemic lupus erythematous; or 3) myositis. [1970] [1971] [1972] [1973] [1974] , when all fifty-year-old men living in Uppsala County, Sweden, were invited to a health survey, initially focusing at identifying risk factors for cardiovascular disease. Out of a total of 2841 men born in 1920-1924, 2322 (82%) agreed to participate in the study. Since then, the cohort has been reinvestigated several times. For the present analysis peripheral blood DNA from 108 men were randomly selected from 296 participants of health investigation at 88 years of age. For a few selected cases displaying large-scale genetic changes, DNA obtained at 70, 77, and 82 years investigations was also used. Informed consent from all participating subjects was obtained.
g ADVANCE: The dataset is derived from Atherosclerotic Disease, Vascular Function, and Genetic Epidemiology (ADVANCE) study; a genome-wide association analysis of coronary artery disease (refs. 30 ; 31 ). The peripheral blood DNA from healthy controls and diseased individuals was collected in Kaiser
Permanente clinics in Northern California and at Stanford University, and genotyped on Illumina 550K arrays. We analyzed the LRR and BAF data from 180 control individuals of European descent who had no evidence of cardiovascular disease. The age range for these controls was 33-55 years. a -The chromosome segment indicated has been covered by a maximum density of overlapping oligonucleotide probes on the Nimblegen 135K custom array. The overall description of the Nimblegen validation array is provided in Supplemental Figure 6 and Materials and Methods.
c -Range of sizes in base pairs is given when CNVs that were validated on Nimblegen array were not of identical sizes. Positions of primers are according to NCBI36/hg18 genome assembly. UCE3 and UCE6 are Ultra Conserved Elements on chromosomes 3 and 6, respectively, which were used as controls. Samples collected in the first sampling are denoted as "A" and samples from the second sampling 10 years later are referred to as "B". Genotyping quality was calculated by the Nexus 5 software (Biodiscovery, Inc. CA, USA). Quality criteria for inclusion of pairs in the analysis; NQ < 0.1 for all individuals and maximum NQ difference within pairs of 0.02.
